CTRI/2015/05/005830

Methods	Randomised, parallel group, multiple arm trial Date of study: 10/12/2013 (starting date) Location: India
Participants	Total sample size: 120 Inclusion criteria: Be diagnosed to be suffering exclusively from Palmo‐plantar psoriasis either by clinical examination or histopathology if required will be included in palmoplantar psoriasis group Be diagnosed to be suffering from psoriasis vulgaris having more than 20% BSA will be included in psoriasis vulgaris group Have completed 18 years of age Exclusion criteria: Hypersensitivity to drug or intolerance to the study medication Pregnant and lactating Clinically significant cardiovascular, haematological, pancreatic, metabolic neurological or any other laboratory anomaly, which in the judgement of investigator, would interfere in participation in study or proper evaluation On any other systemic drugs therapy which in the judgement of investigator may interfere with interpretation of results History of TB or chest X‐ray showing evidence of any infective pathology
Interventions	Intervention 1: acitretin: orally, 25‐50 mg/day, daily single dose Total duration: 90 days Intervention 2: ciclosporin: orally 2.5‐5 mg/kg/day, daily in 2 divided doses Total duration: 90 days Intervention 3: methotrexate: orally 7.5‐15 mg/week in 3 divided doses Total duration: 90 days Control Intervention 1: palmoplantar psoriasis: variant of psoriasis in which only palms and soles are affected Control Intervention 2: psoriasis vulgaris: variant of psoriasis in which lesions appear on body skin
Outcomes	At 90 days 75% reduction in PASI or modified PASI 75% reduction in BSA 75% reduction in psoriasis severity index. Timepoint: 90 days DLQI
Notes	Starting date: 10‐12‐2013. Recruitment status: open to recruitment We sent an email to Prof. Shah (5 and 12 January 2017) without response